{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:55:48Z","timestamp":1792090548113,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1687,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["819775"],"award-info":[{"award-number":["819775"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00655"],"award-info":[{"award-number":["PI19\/00655"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2019-107332RB-I00"],"award-info":[{"award-number":["PID2019-107332RB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["819775"],"award-info":[{"award-number":["819775"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00655"],"award-info":[{"award-number":["PI19\/00655"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2019\u2010107332RB\u2010I00"],"award-info":[{"award-number":["PID2019\u2010107332RB\u2010I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%. The natural evolution of cardiac amyloidosis begins with the deposition of amyloid material in the myocardium, with LVH ensuing at later stages. With current imaging modalities, it is possible to detect TTR cardiac amyloidosis before the hypertrophic stage. The aim of this study was to determine the prevalence of TTR cardiac amyloidosis in HFpEF patients without LVH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The study prospectively enrolled patients admitted for HF with LV ejection fraction (LVEF) \u2265 50% and LV wall thickness &amp;lt;12 mm. TTR cardiac amyloidosis was diagnosed according to accepted criteria, which include positive cardiac 99-Tc-DPD scintigraphy in the absence of monoclonal protein expansion in blood. Transthyretin gene sequencing was performed in positive patients. From July 2017 to January 2020, 329 patients with HFpEF and LV thickness &amp;lt;12 mm were identified. After exclusions, 58 patients completed the study with cardiac scintigraphy (79 years, 54% men; median LVEF 60% and LV wall thickness 10.5 mm). Three patients (5.2%) were positive for TTR cardiac amyloidosis; genetic analysis excluded the presence of hereditary TTR amyloidosis. Positive patients baseline characteristics (84 years, 67% men, LVEF 60%, and LV wall thickness 11 mm) were similar to patients without TTR, except for troponin levels (0.05 vs. 0.02 ng\/mL, P = 0.03) and glomerular filtration rate (82 vs. 60 mL\/min, P = 0.032), which were higher in TTR patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a cohort of patients with HFpEF without LVH, the prevalence of TTR cardiac amyloidosis was 5%. Early diagnosis of cardiac involvement in TTR amyloidosis (before manifest LVH) would seem recommendable because newly approved specific treatments can prevent additional deposition of amyloid material.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13360","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T02:50:38Z","timestamp":1620528638000},"page":"2856-2865","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Prevalence of Transthyretin Amyloidosis in Patients with Heart Failure and No Left Ventricular Hypertrophy"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-2546","authenticated-orcid":false,"given":"Ana","family":"Devesa","sequence":"first","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Melchor Fern\u00e1ndez Almagro, 3, Madrid, 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Camblor Blasco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Pello L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Askari","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital- Quironsalud , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-9325","authenticated-orcid":false,"given":"Gregoria","family":"Lape\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital- Quironsalud , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9272-0547","authenticated-orcid":false,"given":"Sandra","family":"G\u00f3mez Talavera","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Melchor Fern\u00e1ndez Almagro, 3, Madrid, 28029 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-3657","authenticated-orcid":false,"given":"Mikel","family":"Taibo Urqu\u00eda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-5994","authenticated-orcid":false,"given":"Celia","family":"Rodr\u00edguez Olleros","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital- Quironsalud , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-0999","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]},{"name":"Universidad Aut\u00f3noma de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Melchor Fern\u00e1ndez Almagro, 3, Madrid, 28029 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5975-5761","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Ace\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IIS - Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital - Quironsalud , Av. Reyes Cat\u00f3licos, 2, Madrid, 28040 ,","place":["Spain"]},{"name":"Universidad Aut\u00f3noma de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"2026012114211882900_ehf213360-bib-0001","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114211882900_ehf213360-bib-0002","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114211882900_ehf213360-bib-0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114211882900_ehf213360-bib-0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114211882900_ehf213360-bib-0005","volume-title":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity","author":"WHO","year":"2011"},{"key":"2026012114211882900_ehf213360-bib-0006","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol Elsevier Masson SAS"},{"key":"2026012114211882900_ehf213360-bib-0007","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114211882900_ehf213360-bib-0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114211882900_ehf213360-bib-0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114211882900_ehf213360-bib-0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ehjci\/jet284","article-title":"Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study","volume":"15","author":"Kou","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114211882900_ehf213360-bib-0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HPC.0000000000000183","article-title":"Transthyretin cardiac amyloidosis as diagnosed by 99mTc-PYP scanning in patients with acute heart failure and preserved ejection fraction","volume":"18","author":"Presti","year":"2019","journal-title":"Crit Pathw Cardiol"},{"key":"2026012114211882900_ehf213360-bib-0012","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012114211882900_ehf213360-bib-0013","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ejhf.1039","article-title":"Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis","volume":"20","author":"Siegismund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114211882900_ehf213360-bib-0014","doi-asserted-by":"crossref","first-page":"16291","DOI":"10.1073\/pnas.1315112110","article-title":"Amyloid and inflammation","volume":"110","author":"Gorevic","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012114211882900_ehf213360-bib-0015","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114211882900_ehf213360-bib-0016","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026012114211882900_ehf213360-bib-0017","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"2026012114211882900_ehf213360-bib-0018","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114211882900_ehf213360-bib-0019","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13360","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13360","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2856\/65569356\/eschf_8_4_2856.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2856\/65569356\/eschf_8_4_2856.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:26:01Z","timestamp":1769023561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/4\/2856\/8344430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,8]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13360","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"2020-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}